SPRYCEL DIN 02293137
Status: Marketed
Holder: BRISTOL-MYERS SQUIBB CANADA
Molecule: DASATINIB (DASATINIB MONOHYDRATE)
Available to quote
Health Canada record
| Active ingredient(s) | DASATINIB (DASATINIB MONOHYDRATE) 50 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EA02 DASATINIB |
| Original market date | 13-Apr-2007 |
| Current status date | 13-Apr-2007 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DASATINIB (DASATINIB MONOHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02562502 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 100 MG | Marketed |
| 02562499 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 80 MG | Marketed |
| 02562480 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 70 MG | Marketed |
| 02562472 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 50 MG | Marketed |
| 02562464 | APO-DASATINIB TABLETS | APOTEX INC | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 20 MG | Marketed |
| 02293129 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 20 MG | Marketed |
| 02293145 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 70 MG | Marketed |
| 02320193 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 100 MG | Marketed |
| 02360810 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 80 MG | Marketed |
| 02360829 | SPRYCEL | BRISTOL-MYERS SQUIBB CANADA | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 140 MG | Marketed |
| 02478358 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 100 MG | Marketed |
| 02478331 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 80 MG | Marketed |
| 02478323 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 70 MG | Marketed |
| 02478315 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 50 MG | Marketed |
| 02478307 | TEVA-DASATINIB | TEVA CANADA LIMITED | Tablet | DASATINIB (DASATINIB MONOHYDRATE) 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 8672 | 2007-03-26 | New Drug Submission (NDS) |